1. Scrip

Dupixent Gets A Yes For COPD From The CHMP

 
• By Elizabeth Cairns

Sanofi and Regeneron could have the first biologic on the market for COPD – and a potentially better one is in the works.    

Lungs icon, anatomy, health care concept
• Source: Shutterstock

Even as it stumbles in the US in its journey to become the first-ever targeted therapy for COPD, Dupixent (dupilumab) has taken a step closer to Europe. Today the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave its imprimatur to Sanofi and Regeneron Pharmaceuticals, Inc.’s anti-inflammatory juggernaut for the lung disease, and approval could come swiftly.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.

Novartis Gains Further Renal Territory With Regulus Acquisition

 
• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.